Similar Papers

Paper Title
Journal
Date
Author
A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
Taofeek K Owonikoko ... Suresh S Ramalingam
Journal of Thoracic Oncology | VOL. 7
Taofeek K Owonikoko, et. al.Taofeek K Owonikoko ... Suresh S Ramalingam
01 May 2012
Efficacy results of first-line chemotherapy re-challenge in sensitive small cell lung cancer (SCLC): A retrospective multicenter analysis.
Giovenzio Genestreti ... Claudio Dazzi
Journal of Clinical Oncology | VOL. 31
Giovenzio Genestreti, et. al.Giovenzio Genestreti ... Claudio Dazzi
20 May 2013
Therapeutic uses of topotecan for thoracic malignancies
...
Oncology Reviews | VOL. 3
, et. al. ...
08 May 2009
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
Joachim Von Pawel ... Léon Bosquée
Journal of Clinical Oncology | VOL. 32
Joachim Von Pawel, et. al.Joachim Von Pawel ... Léon Bosquée
10 Nov 2014
View more papers

More From: European Journal of Cancer

Paper Title
Journal
Date
Author
Cancer-Specific Utility Instrument for Health Economic Evaluations: A Synopsis of the EORTC QLU-C10D User Manual and Current Validity Evidence
Simone Seyringer ... Eva M Gamper
European Journal of Cancer | VOL. -
Simone Seyringer, et. al.Simone Seyringer ... Eva M Gamper
01 Jan 2025
Editorial Board
-
European Journal of Cancer | VOL. 215
--
01 Jan 2025
Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results
Annalisa Trama ... Salvatore Provenzano
European Journal of Cancer | VOL. -
Annalisa Trama, et. al.Annalisa Trama ... Salvatore Provenzano
01 Jan 2025
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: analysis of individual patient-level data from daratumumab clinical trials
Kwee Yong ... Binod Dhakal
European Journal of Cancer | VOL. 215
Kwee Yong, et. al.Kwee Yong ... Binod Dhakal
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.